DoD Rare Cancers, Idea Development Award
ID: 353641Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353641
Timeline
    Description

    The Department of the Army, through the U.S. Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Rare Cancers Research Program (RCRP) Idea Development Award to support innovative research aimed at addressing rare cancers, which are defined as those affecting six or fewer individuals per 100,000 annually in the U.S. This grant opportunity encourages applications that demonstrate a strong scientific rationale and preliminary data relevant to rare cancers, with a focus on potential high-impact advancements in cancer biology, research models, or novel therapeutic strategies. The total estimated funding for this program is $6.16 million, with a maximum request of $350,000 per project for up to three years, and applications are due by September 23, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT924524RCRPIDA_GG.pdf
    The Department of Defense (DOD) is announcing the FY24 Rare Cancers Research Program (RCRP), specifically offering the Idea Development Award to encourage innovative research on rare cancers, defined as those affecting six or fewer people per 100,000 annually in the U.S. The funding opportunity includes a total of $17.5 million for this fiscal year, with a maximum request of $350,000 per project for up to three years. Applicants must demonstrate the relevance of their research to military personnel, veterans, and the general public, and address at least one of the program's focus areas: cancer biology, research models, or novel therapeutic strategies. The submission process follows a two-step approach: pre-application submission via eBRAP and full application via Grants.gov, with strict adherence to deadlines. Eligible applicants include both extramural and intramural organizations, with independent investigators at or above the Assistant Professor level acting as Principal Investigators. The review process will evaluate the applications based on technical merit, impact on rare cancer outcomes, and the overall effectiveness of the proposed research strategy. The program aims to promote research with the potential for significant advancements in addressing rare cancers and improving patient outcomes.
    Similar Opportunities
    DoD Arthritis Research, Clinical Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Arthritis Research Clinical Research Award (ATRP CRA) to support clinical research aimed at improving the understanding and management of various forms of arthritis, particularly in military personnel and their families. This grant program encourages innovative research proposals that address disease-specific factors and interventions, with a focus on enhancing patient outcomes and informing clinical care or policy. With an estimated total funding of $6 million, the program anticipates awarding approximately three grants, including one for a clinical trial, with applications due by October 30, 2024, and a pre-application deadline of October 16, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Reconstructive Transplant Research, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is inviting applications for the FY24 Reconstructive Transplant Research Program (RTRP) Investigator-Initiated Research Award, aimed at advancing reconstructive transplant research and improving healthcare for military service members and veterans. This grant opportunity seeks proposals that focus on vascularized composite allotransplantation (VCA) and immunotherapy, emphasizing the optimization of immunosuppressive techniques, identification of noninvasive biomarkers for graft rejection monitoring, and development of tissue preservation strategies. With an estimated total program funding of $4 million, individual principal investigator applications can receive up to $1 million, while multiple principal investigator collaborations may secure up to $1.5 million, contingent upon successful peer review. The pre-application deadline is August 7, 2024, and the full application deadline is October 23, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DOD Glioblastoma, Resource Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Resource Development Award, aimed at enhancing research capabilities for glioblastoma, a malignant brain tumor. This grant supports the development of preclinical model systems that improve the understanding and treatment of glioblastoma, with a focus on innovative approaches such as animal models, organoids, and patient-derived xenografts. With a total funding pool of $4 million, the program anticipates awarding up to five grants, each capped at $500,000 over three years. Interested applicants must submit a pre-application by November 6, 2024, followed by a full application due by November 20, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DOD Glioblastoma, Hypothesis Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Hypothesis Development Award, aimed at funding innovative research to improve glioblastoma patient outcomes. This grant supports exploratory projects that address significant issues in glioblastoma research, particularly in areas such as drug delivery and biomarker identification, without requiring preliminary data. The total estimated funding for this program is approximately $4.64 million, with an expected 13 awards to be made, each with a funding limit of $200,000 for single principal investigators and $300,000 for partnering teams, over a performance period of up to two years. Interested applicants must submit a Letter of Intent by November 6, 2024, followed by a full application by November 20, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.
    DoD Reconstructive Transplant, Idea Discovery Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Reconstructive Transplant Idea Discovery Award, a federal grant aimed at supporting innovative and high-risk research in reconstructive transplant and immunotherapy. This grant seeks to generate robust data that can lead to new scientific investigations, particularly focusing on enhancing immunosuppression techniques and advancing tissue preservation strategies relevant to military personnel and veterans. With an estimated total program funding of $2.5 million, the award will provide up to $500,000 for each selected project over a two-year period, contingent upon the availability of federal funds and the merit of applications. Interested applicants must submit a pre-application by August 7, 2024, followed by a full application due by October 23, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Reconstructive Transplant, Advanced Technology Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Reconstructive Transplant Advanced Technology Development Award, aimed at supporting innovative research in reconstructive transplantation for injured Service Members and Veterans. This grant opportunity encourages the development of products such as drugs, biologic agents, and clinical practice guidelines, with a focus on enhancing techniques and access to reconstructive transplantation. The program has an estimated total funding of $3.5 million, with awards of up to $1.5 million available for applications involving multiple principal investigators. Interested applicants must submit a pre-application by August 7, 2024, followed by a full application due by October 23, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Reconstructive Transplant, Qualitative Research Validation and Implementation Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Reconstructive Transplant, Qualitative Research Validation and Implementation Award, aimed at advancing qualitative research in reconstructive transplantation. This grant seeks to validate and implement resources developed from previous studies related to vascularized composite allotransplantation (VCA), focusing on improving outcomes for service members, veterans, and the broader community. The total funding available for this opportunity is $500,000, with a maximum budget for individual projects capped at the same amount, and applications are due by October 23, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Arthritis, Focused Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the DoD Arthritis Focused Research Award (Funding Opportunity Number: HT942524ATRPFRA) to support innovative research aimed at improving patient care for individuals affected by arthritis. This grant encourages applications that explore high-risk, high-reward research addressing various types of arthritis, including osteoarthritis and rheumatoid arthritis, with a particular focus on the implications for military personnel and their families. The total funding available for FY24 is approximately $2.5 million, with individual project budgets capped at $750,000 for Research Level 2 and $500,000 for Research Level 1. Interested applicants must submit a pre-application by October 16, 2024, and a full application by October 30, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    Toxic Exposures Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a funding opportunity for the Fiscal Year 2024 Toxic Exposures Clinical Trial Award under the Toxic Exposures Research Program (TERP). This grant aims to support the rapid implementation of clinical trials that address health outcomes related to military-related toxic exposures, with a focus on prevention, treatment, and management of associated symptoms and diseases. The program emphasizes the importance of collaboration between the Department of Defense and the Department of Veterans Affairs, seeking proposals that align with specific program goals and topic areas, such as neurotoxin exposure and Gulf War Illness. The total estimated funding for this initiative is $10.4 million, with applications due by November 7, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the NCI Small Grants Program for Cancer Research (R03) for the years 2023 to 2025. This funding opportunity is designed to support small-scale research projects on cancer that can be completed within a two-year timeframe and with limited resources, including pilot studies, secondary data analyses, and the development of research methodologies or technologies. Grants of up to $50,000 per year are available to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations. Interested parties should submit their applications electronically via Grants.gov, with the first submission deadline having been January 22, 2023, and subsequent deadlines continuing through 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.